Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Provectus Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Provectus Biopharmaceuticals Announces License Agreement for Antimicrobial Treatment
Details : Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.
Brand Name : RB-PDT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Provectus Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Brand Name : Tivicay
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?